INMB · Insider Trading
INmune Bio Inc. Common stock
Every open-market purchase and sale reported by INMB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-23 | Ronnie Duane Clark | Director | A | +100,000 deriv. | — |
| 2026-09-17 | James Sapirstein | Director | A | +100,000 deriv. | — |
| 2026-07-07 | David J Moss | Chief Executive Officer | M | +9,014 | +$12.62K |
| 2026-07-07 | Scott Juda | Director | M | +14,801 | +$20.72K |
| 2026-07-07 | Mark William Lowdell | Chief Scientific Officer | M | +7,211 | +$10.10K |
| 2025-12-02 | Scott Juda | Director | A | +150,000 deriv. | — |
| 2025-12-02 | Mark William Lowdell | Chief Scientific Officer | A | +600,000 deriv. | — |
| 2025-12-02 | Marcia Allen | Director | A | +150,000 deriv. | — |
| 2025-12-02 | Cory Randall Ellspermann | CFO | A | +300,000 deriv. | — |
| 2025-12-02 | James Kelly Ganjei | Director | A | +150,000 deriv. | — |
| 2025-12-02 | Timothy j Schroeder | Director | A | +150,000 deriv. | — |
| 2025-12-02 | David J Moss | Chief Executive Officer | A | +750,000 deriv. | — |
| 2025-11-18 | Mark William Lowdell | Chief Scientific Officer | MIXED | — | — |
| 2025-11-18 | Timothy j Schroeder | Director | MIXED | — | — |
| 2025-11-18 | James Kelly Ganjei | Director | MIXED | — | — |
| 2025-11-18 | Marcia Allen | Director | MIXED | — | — |
| 2025-11-18 | David J Moss | Chief Executive Officer | MIXED | — | — |
| 2025-11-18 | Scott Juda | Director | MIXED | — | — |
| 2025-11-18 | Cory Randall Ellspermann | Interim CFO | MIXED | — | — |
| 2024-12-09 | Mark William Lowdell | Chief Scientific Officer | A | +140,000 deriv. | — |
| 2024-12-09 | Raymond Joseph Tesi | President and CEO | A | +226,000 deriv. | — |
| 2024-12-09 | David J Moss | Chief Financial Officer | A | +223,000 deriv. | — |
| 2024-12-09 | James Kelly Ganjei | Director | A | +32,500 deriv. | — |
| 2024-12-09 | Timothy j Schroeder | Director | A | +32,500 deriv. | — |
| 2024-12-09 | Marcia Allen | Director | A | +32,500 deriv. | — |
| 2024-12-09 | Scott Juda | Director | A | +32,500 deriv. | — |
| 2024-09-30 | David J Moss | Chief Financial Officer | Buy | +10,000 | +$52.87K |
| 2024-09-16 | David J Moss | Chief Financial Officer | Buy | +7,690 | +$49.02K |
| 2024-09-16 | Raymond Joseph Tesi | President and CEO | Buy | +15,380 | +$98.05K |
| 2024-06-26 | Scott Juda | Director | Buy | +5,000 | +$36.35K |
| 2024-06-12 | Raymond Joseph Tesi | President and CEO | A | +37,882 deriv. | — |
| 2024-05-16 | Raymond Joseph Tesi | President and CEO | A | +160,000 deriv. | — |
| 2024-05-16 | Mark William Lowdell | Chief Scientific Officer | A | +100,000 deriv. | — |
| 2024-05-16 | Marcia Allen | Director | A | +12,500 deriv. | — |
| 2024-05-16 | Timothy j Schroeder | Director | A | +12,500 deriv. | — |
| 2024-05-16 | Edgardo Baracchini Jr | Director | A | +12,500 deriv. | — |
| 2024-05-16 | David J Moss | Chief Financial Officer | A | +160,000 deriv. | — |
| 2024-05-16 | Scott Juda | Director | A | +12,500 deriv. | — |
| 2024-05-16 | James Kelly Ganjei | Director | A | +12,500 deriv. | — |
| 2024-04-24 | Scott Juda | Director | Buy | +29,603 | +$246.30K |
| 2024-04-24 | Raymond Joseph Tesi | President and CEO | Buy | +18,028 | +$149.99K |
| 2024-04-24 | Mark William Lowdell | Chief Scientific Officer | Buy | +14,423 | +$120.00K |
| 2024-04-24 | David J Moss | CFO, Treasurer & Secretary | Buy | +18,028 | +$149.99K |
| 2024-04-23 | David J Moss | CFO, Treasurer & Secretary | A | +18,028 | +$149.99K |
| 2024-04-23 | Mark William Lowdell | Chief Scientific Officer | A | +14,423 | +$120.00K |
| 2024-04-23 | Raymond Joseph Tesi | President and CEO | A | +18,028 | +$149.99K |
| 2024-04-23 | Scott Juda | Director | A | +29,603 | +$246.30K |
| 2023-11-13 | Scott Juda | Director | Buy | +7,000 | +$48.65K |
| 2023-07-14 | Timothy j Schroeder | Director | Sell | −10,000 | −$110.08K |
| 2023-03-20 | David J Moss | CFO, Treasurer & Secretary | Buy | +2,500 | +$16.06K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Raymond Joseph Tesi | President and CEO | 1,554,106 | $2.96M |
| Mark William Lowdell | Chief Scientific Officer | 1,518,017 | $2.89M |
| David J Moss | Chief Executive Officer | 1,294,883 | $2.47M |
| Scott Juda | Director | 158,007 | $301.00K |
| Timothy j Schroeder | Director | 82,187 | $156.57K |
| James Kelly Ganjei | Director | 17,793 | $33.90K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INMB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.